Yahoo Finance

Truist lowered the firm’s price target on Ultragenyx (RARE) to $100 from $140 and keeps a Buy rating on the shares. The company’s Q1 results were in-line and the management reiterated its FY25 revenue guidance, though the firm’s price target is cut on tampered outlook for gene therapy programs, the analyst tells investors in a research note.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.

• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on RARE:

Disclaimer & DisclosureReport an Issue

• Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Promising Pipeline and Consistent Demand

• Ultragenyx Pharmaceutical: Undervalued Stock with Promising Pipeline and Strategic Entry Point

• Investors will be rewarded for buying Ultragenyx at $35, says Citi

• Buy Recommendation for Ultragenyx Pharmaceutical Driven by Strong Commercial Execution and Promising Pipeline

• Ultragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating